

**Supplemental Table I.** Baseline patient characteristics subdivided by disease activity and damage categories

Characteristic	Baseline CLASI-A $\leq 9$ , N = 50	Baseline CLASI-A >9, N = 33	Baseline CLASI-D 0-4, N = 36	Baseline CLASI-D 5-9, N = 19	Baseline CLASI-D $\geq 10$ , N = 28
CLASI-A, mean (SD)	3.70 (2.68)	20.97 (8.86)	8.94 (10.21)	7.00 (7.99)	15.07 (10.69)
CLASI-D, mean (SD)	5.16 (4.95)	13.79 (12.54)	1.31 (1.65)	6.32 (1.06)	19.50 (9.13)
Sex, n (%)					
Female	39 (78.00)	29 (87.88)	31 (86.11)	14 (73.68)	23 (82.14)
Male	11 (22.00)	4 (12.12)	5 (13.89)	5 (26.32)	5 (17.86)
Race, n (%)					
White	31 (62.00)	18 (54.55)	30 (83.33)	11 (57.89)	8 (28.57)
Black	18 (36.00)	11 (33.33)	4 (11.11)	7 (36.84)	18 (64.29)
Hispanic/Latino	1 (2.00)	3 (9.09)	2 (5.56)	0 (0)	2 (7.14)
Asian	0 (0)	1 (3.03)	0 (0)	1 (5.26)	0 (0)
Age at diagnosis, years, mean (SD)	40.18 (14.98)	37.54 (14.95)	45.89 (15.53)	35.63 (15.72)	32.56 (9.06)
Age at first visit, years, mean (SD)	50.38 (12.56)	46.91 (12.08)	51.79 (13.35)	47.84 (12.38)	46.20 (10.75)
Predominant CLE subtype					
Discoid LE	36 (72.00)	21 (63.64)	16 (44.44)	16 (84.21)	25 (89.29)
Localized	25 (50.00)	6 (18.18)	11 (30.56)	14 (73.68)	6 (21.43)
Generalized	11 (22.00)	15 (45.45)	5 (13.89)	2 (10.53)	19 (67.86)
Subacute LE	14 (28.00)	12 (36.36)	20 (55.56)	3 (15.79)	3 (10.71)
Annular	4 (8.00)	4 (12.12)	7 (19.44)	0 (0)	1 (3.57)
Papulosquamous	12 (24.00)	10 (30.30)	17 (47.22)	3 (15.79)	2 (7.14)
Systemic LE involvement, n (%)	13 (26.00)	10 (30.30)	6 (16.67)	4 (21.05)	13 (46.43)
Discoid	10 (20.00)	10 (30.30)	3 (8.33)	4 (21.05)	13 (46.43)
Localized	5 (10.00)	2 (6.06)	2 (5.56)	4 (21.05)	1 (3.57)
Generalized	5 (10.00)	8 (24.24)	1 (2.78)	0 (0)	12 (42.86)
Subacute	3 (6.00)	0 (0)	3 (8.33)	0 (0)	0 (0)
Annular	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Papulosquamous	3 (6.00)	0 (0)	3 (8.33)	0 (0)	0 (0)
Disease duration at baseline visit, years, mean (SD)	10.11 (12.24)	9.37 (8.61)	5.90 (8.68)	12.21 (14.69)	13.35 (8.91)
Duration of follow-up per patient, years, mean (SD)	4.06 (1.84)	3.52 (1.89)	3.60 (1.51)	4.21 (2.00)	3.92 (2.19)
No. follow-up visits per patient, mean (SD)	7.43 (3.00)	7.70 (4.71)	6.83 (3.06)	7.84 (3.35)	8.21 (4.68)
Smoking status, n (%)					
Nonsmoker	26 (52.00)	12 (36.36)	18 (50.00)	11 (57.89)	9 (32.14)
Current smoker	16 (32.00)	17 (51.52)	12 (33.33)	5 (26.32)	16 (57.14)
Past smoker	8 (16.00)	4 (12.12)	6 (16.67)	3 (15.79)	3 (10.71)

CLASI-A, Cutaneous Lupus Erythematosus Disease Area and Severity Index activity; CLASI-D, Cutaneous Lupus Erythematosus Disease Area and Severity Index damage; CLE, cutaneous lupus erythematosus; LE, lupus erythematosus; SD, standard deviation.

**Supplemental Table II.** Patient characteristics and disease activity, average change score and variability over time

Patient characteristic	N	Average change in CLASI-A score, mean (SD)	Disease progression, n (%)			Variability over time flares/year, mean (SD)
			Improved	Stable	Worsened	
Baseline CLASI-A score						
≤9	50	0.93 (4.20)	7 (14.00)	31 (62.00)	12 (24.00)	0.5 (0.31)
>9	33	-6.71 (7.93)	24 (72.73)	7 (21.21)	2 (6.06)	0.53 (0.59)
P value		<b>&lt;.0001</b>		<b>&lt;.0001</b>		.75
Baseline CLASI-D score						
0-4	36	-1.77 (7.95)	10 (27.78)	20 (55.56)	6 (16.67)	0.54 (0.36)
5-9	19	1.49 (7.66)	7 (36.84)	9 (47.37)	3 (15.79)	0.42 (0.28)
≥10	28	-2.96 (5.21)	14 (50.00)	9 (32.14)	5 (17.86)	0.55 (0.60)
P value		.35		.40		.53
Sex						
Female	68	-1.94 (6.52)	25 (36.76)	32 (47.06)	11 (16.18)	0.54 (0.47)
Male	15	-2.89 (9.18)	6 (40.00)	6 (40.00)	3 (20.00)	0.39 (0.26)
P value		.97	.87			.13
Race						
White	49	-2.52 (8.36)	19 (38.78)	21 (42.86)	9 (18.37)	0.51 (0.36)
Black	29	-1.03 (3.75)	8 (27.59)	17 (58.62)	4 (13.79)	0.53 (0.59)
Other	5	-4.36 (7.37)	4 (80.00)	0 (0)	1 (20.00)	0.52 (0.21)
P value		.38	.14			.85
Age at first visit, years						
≤50	46	-1.14 (6.72)	17 (36.96)	19 (41.30)	10 (21.74)	0.48 (0.34)
>50	37	-3.31 (7.27)	14 (37.84)	19 (51.35)	4 (10.81)	0.56 (0.54)
P value		.24	.39			NA
CLE subtype						
Localized DLE	31	-0.98 (2.94)	10 (32.26)	19 (61.29)	2 (6.45)	0.53 (0.52)
Generalized DLE	26	-1.86 (5.18)	9 (34.62)	13 (50.00)	4 (15.38)	0.57 (0.35)
SACLE	26	-3.70 (10.95)	12 (46.15)	6 (23.08)	8 (30.77)	0.52 (0.43)
P value		.76		<b>.03</b>		.71
Systemic LE Involvement						
No	60	-2.34 (7.68)	23 (38.33)	27 (45.00)	10 (16.67)	0.53 (0.48)
Yes	23	-1.51 (4.99)	8 (34.78)	11 (47.83)	4 (17.39)	0.46 (0.31)
P value		.97	.96			.78
Disease duration at baseline visit, years						
>1	65	-1.47 (6.30)	23 (35.38)	30 (46.15)	12 (18.46)	0.51 (0.46)
≤1	18	-4.43 (8.99)	8 (44.44)	8 (44.44)	2 (16.67)	0.55 (0.40)
P value		.38	.68			.55
Smoking status						
Current smoker	33	-2.10 (8.26)	12 (36.36)	12 (36.36)	9 (27.27)	0.46 (0.34)
Past or never smoker	50	-2.12 (6.15)	19 (38.00)	26 (52.00)	5 (10.00)	0.55 (0.50)
P value		.23	.10			.76

Statistically significant values are in bold.

CLASI-A, Cutaneous Lupus Erythematosus Disease Area and Severity Index activity; CLASI-D, Cutaneous Lupus Erythematosus Disease Area and Severity Index damage; CLE, cutaneous lupus erythematosus; DLE, discoid lupus erythematosus; LE, lupus erythematosus; NA, not applicable; SACLE, subacute lupus erythematosus; SD, standard deviation.

**Supplemental Table III.** Patient characteristics associated with disease damage and average change score

Patient characteristic	N	Average change in CLASI-D score, mean (SD)	Disease progression, n (%)		
			Improved	Stable	Worsened
Baseline CLASI-A score					
≤9	50	0.70 (3.06)	5 (10.00)	36 (72.00)	9 (18.00)
>9	33	0.84 (5.09)	6 (18.18)	18 (54.55)	9 (27.27)
<i>P</i> value		.46	.26		
Baseline CLASI-D score					
0-4	36	1.81 (2.35)	0 (0)	29 (80.56)	7 (19.44)
5-9	19	1.52 (3.82)	1 (5.26)	13 (68.42)	5 (26.32)
≥10	28	-1.12 (5.02)	10 (35.71)	12 (42.86)	6 (21.43)
<i>P</i> value		<b>.004</b>	<b>.0005</b>		
Sex					
Female	68	0.83 (3.85)	8 (11.76)	45 (66.18)	15 (22.06)
Male	15	0.39 (4.56)	3 (20.00)	9 (60.00)	3 (20.00)
<i>P</i> value		.58	.70		
Race					
White	49	0.75 (4.08)	6 (12.24)	34 (69.39)	9 (18.37)
Black	29	1.15 (3.93)	4 (13.79)	16 (55.17)	9 (31.03)
Other	5	-1.54 (2.55)	1 (20.00)	4 (80.00)	0 (0)
<i>P</i> value		.17	.48		
Age at first visit, years					
≤50	46	1.08 (3.77)	6 (13.04)	29 (63.04)	11 (23.91)
>50	37	0.35 (4.21)	5 (13.51)	25 (67.57)	7 (18.92)
<i>P</i> value		.36	.86		
CLE subtype					
Localized DLE	31	0.68 (3.14)	3 (9.68)	24 (77.42)	4 (12.90)
Generalized DLE	26	0.65 (5.03)	5 (19.23)	12 (46.15)	9 (34.62)
SCLE	26	0.95 (3.98)	3 (11.54)	18 (69.23)	5 (19.23)
<i>P</i> value		.92	.17		
Systemic LE involvement					
No	60	0.82 (3.92)	7 (11.67)	41 (68.33)	12 (20.00)
Yes	23	0.57 (4.17)	4 (17.39)	13 (56.52)	6 (26.09)
<i>P</i> value		.88	.59		
Disease Duration at baseline visit, years					
>1	65	0.25 (4.04)	11 (16.92)	42 (64.62)	12 (18.46)
≤1	18	2.57 (3.15)	0 (0)	12 (66.67)	6 (33.33)
<i>P</i> value		<b>.02</b>	.11		
Smoking status					
Current smoker	33	0.42 (4.66)	6 (18.18)	20 (60.61)	7 (21.21)
Past or never smoker	50	0.97 (3.46)	5 (10.00)	34 (68.00)	11 (22.00)
<i>P</i> value		.73	.55		

Statistically significant values are in bold.

CLASI-A, Cutaneous Lupus Erythematosus Disease Area and Severity Index activity; CLASI-D, Cutaneous Lupus Erythematosus Disease Area and Severity Index damage; CLE, cutaneous lupus erythematosus; DLE, discoid lupus erythematosus; LE, lupus erythematosus; SCLE, subacute lupus erythematosus; SD, standard deviation.